-
Media Release
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
-
Media Release
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
-
Story
Addressing unmet needs for inherited neuromuscular diseases -
Media Release
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
-
Media Release
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
-
Media Release
Novartis publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis
-
Interior Page
Neuroscience
-
Media Release
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
-
Media Release
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
-
Media Release
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
-
Story
In neuroscience, “an inflection point in knowledge and technology” -
Media Release
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)